Global segment ranking · Healthtech › Clinical software

The world’s most valuable clinical software companies

Hospital- and clinician-facing software: AI scribes and clinical documentation, clinical decision support, health-system data platforms, care coordination and hospital operations. Ranked worldwide by AI-estimated valuation. The market sets the value; our AI estimates it.

Edition 0 (beta) · Published September 29, 2026 Twice a yearNext edition: January 1, 2027· Claude · multi-AI consensus in a future edition· Published method· Order never changed by a human

Key metrics for this segment: adoption, revenue, total raised. Figures as published by each company or the press, dated, not recalculated. The AIs weigh them alongside funding history and comparables.

Not in this segment. Clinic management software for independent practices, telemedicine, appointment booking, imaging and medical AI, connected devices and mental health each have their own segment. A company appears in one segment only. Method

The segment at a glance

14companies ranked

6companies on the radar

6countries in the ranking

4listed benchmarks

Sources: STAT, Fierce Healthcare, Becker's Hospital Review, Axios Pro, Fortune, MobiHealthNews, Tech.eu, Business News Australia, Calcalist, Sacra, PR Newswire, BusinessWire, Wikipedia, company announcements. Intention counters will be shown above a threshold of amount and number of Backers.

Rankings by region

Filter the ranking and the Radar. Ranks stay worldwide.

Global ranking · Clinical software

Top 14 Radar Challengers

First edition: no movements yet.

World · 14 ranked companies

#	Company	Last round · Key metrics	Estimated valuation (AI, order of magnitude)	Confidence	Invest
1	OpenEvidenceUnited States · North AmericaSources: 1 · 2 · 3 · 4Is this your company? Report an error	Equity round · USD 250M · Sep 2026Used regularly by more than half of US physicians (2026) · Revenue ~$300M annualized (reported) (mid-2026) · Nearly $1B (2026)	Last known equity round: Equity round · USD 250M · Sep 2026 (led by Andreessen Horowitz and Byers Capital) Published valuation: USD 15bn (Sep 2026) Confidence index: HighMethod	Solid sources	Declare an intent
2	CommureUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Equity round · USD 70M · May 2026500+ organizations, 3,000+ care sites · Revenue: n/d · Total raised: n/d · 2026	Last known equity round: Equity round · USD 70M · May 2026 (led by General Catalyst, with Sequoia Capital, Morgan Stanley) Published valuation: USD 7bn (May 2026) Confidence index: HighMethod	Solid sources	Declare an intent
3	AbridgeUnited States · North AmericaSources: 1 · 2 · 3Is this your company? Report an error	Series E extension · USD 316M · Apr 2026300+ health systems live (2026) · Revenue ~$100M ARR (Sacra estimate) (May 2025) · ~$830M (2026)	Last known equity round: Series E extension · USD 316M · Apr 2026 (led by Andreessen Horowitz, with NVIDIA NVentures, Khosla Ventures) Published valuation: USD 5.3bn (Jun 2025) Confidence index: HighMethod	Solid sources	Declare an intent
4	InnovaccerUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series F · USD 275M · Jan 20257 of the top 10 US health systems; 80M+ patient records · Revenue $200M ARR · Total raised: n/d · 2026	Last known equity round: Series F · USD 275M · Jan 2025 (led by B Capital Group) Published valuation: USD 3.45bn (reported) (Jan 2025) Confidence index: HighMethod	Solid sources	Declare an intent
5	Hippocratic AIUnited States · North AmericaSources: 1 · 2 · 3Is this your company? Report an error	Series C · USD 126M · Nov 2025Adoption: n/d · Revenue: n/d · $404M+ · 2025	Last known equity round: Series C · USD 126M · Nov 2025 (led by Avenir Growth) Published valuation: USD 3.5bn (Nov 2025) Confidence index: HighMethod	Solid sources	Declare an intent
6	Ambience HealthcareUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series C · USD 243M · Jul 2025Key metrics not disclosed	Last known equity round: Series C · USD 243M · Jul 2025 (led by Oak HC/FT and Andreessen Horowitz) Published valuation: over USD 1.25bn (Jul 2025) Confidence index: HighMethod	Solid sources	Declare an intent
7	Heidi HealthAustralia · Asia-PacificSources: 1 · 2Is this your company? Report an error	Series C · USD 100M equity (+ USD 240M growth investment from General Catalyst's Customer Value Fund) · Sep 20262.8M patient visits per week, 190 countries · Revenue $50M ARR · $436.6M (incl. growth investment) · 2026	Last known equity round: Series C · USD 100M equity (+ USD 240M growth investment from General Catalyst's Customer Value Fund) · Sep 2026 (led by Blackbird) Published valuation: USD 900M (Sep 2026) Confidence index: HighMethod	Solid sources	Declare an intent
8	Qualified HealthUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series B · USD 125M · Mar 2026Key metrics not disclosed	Last known equity round: Series B · USD 125M · Mar 2026 (led by NEA) No confirmed published valuation Confidence index: MediumMethod	Partial sources	Declare an intent
9	QventusUnited States · North AmericaSources: 1Is this your company? Report an error	Series D · USD 105M · Jan 2025500,000+ surgeries influenced · Revenue: n/d · Total raised: n/d · 2024	Last known equity round: Series D · USD 105M · Jan 2025 (led by KKR) No confirmed published valuation Confidence index: MediumMethod	Partial sources	Declare an intent
10	Tandem HealthSweden · EuropeSources: 1 · 2Is this your company? Report an error	Series B · EUR 86.5M (~USD 100M) · Sep 202610,000 care organizations in 14 European markets · Revenue: n/d · $160M · 2026	Last known equity round: Series B · EUR 86.5M (~USD 100M) · Sep 2026 (led by Scaleup Europe Fund, with Kinnevik, Northzone) No confirmed published valuation Confidence index: MediumMethod	Partial sources	Declare an intent
11	NablaFrance · EuropeSources: 1 · 2Is this your company? Report an error	Series C · USD 70M · Jun 202585,000+ clinicians, 130+ health organizations · Revenue: n/d · $120M · 2025	Last known equity round: Series C · USD 70M · Jun 2025 (led by HV Capital, with Highland Europe, DST Global) No confirmed published valuation Confidence index: MediumMethod	Partial sources	Declare an intent
12	SukiUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series D · USD 70M · Oct 2024Adoption: n/d · Revenue: n/d · $168M · 2025	Last known equity round: Series D · USD 70M · Oct 2024 (led by Hedosophia) Published valuation: about USD 500M (reported) (Oct 2024) Confidence index: MediumMethod	Partial sources	Declare an intent
13	NavinaIsrael · Middle East & North AfricaSources: 1 · 2Is this your company? Report an error	Series C · USD 55M · Mar 202510,000+ clinicians, 1,300 clinics · Revenue: n/d · $100M · 2025	Last known equity round: Series C · USD 55M · Mar 2025 (led by Goldman Sachs Alternatives (Growth Equity)) No confirmed published valuation Confidence index: MediumMethod	Partial sources	Declare an intent
14	CortiDenmark · EuropeSources: 1 · 2Is this your company? Report an error	Series B · USD 60M · Sep 2023~100M patients a year · Revenue: n/d · Total raised: n/d · 2023	Last known equity round: Series B · USD 60M · Sep 2023 (led by Prosus Ventures and Atomico) No confirmed published valuation Confidence index: MediumMethod	Partial sources	Declare an intent

Ranking in descending order of AI-estimated valuation, based on public information, following a published method, with no human intervention on the order. Valuation ranges are indicative editorial estimates: neither a financial valuation, nor an offer, nor investment advice. Only the market sets a company’s value, through a funding round or a sale. Edition 0: produced by Claude (Anthropic); a consensus of several AI models will apply in a future edition. Eligibility: at least $1M raised including one equity round, non-listed company, main activity in this segment (AI scribes, clinical decision support, health-system data platforms and care coordination software). Country shown is the country of main operations. Request a correction

Get every new edition

New entries, exits and movements, twice a year.

One e-mail per edition. One-click unsubscribe. No data passed on to third parties.

How to read this ranking

Rank

Companies are ranked by AI-estimated valuation, highest first. The market sets the value; our AI estimates it.

Range

An order of magnitude, never a figure.

Hundreds of k$
Millions $
Tens of M$
Hundreds of M$
Unicorn
Decacorn

Confidence

High: recent published valuation or round (under 24 months).
Medium: older data.
Low: single or unconfirmed source.

Full method →

Invest in clinical software, together

Uback aggregates investment intentions from business angels, family offices, corporates and sector specialists worldwide. Every ranked company already has professional investors on its cap table, who have negotiated a shareholders’ agreement: you don’t start from a blank page.

Strength in numbers

Alone, a small ticket opens no doors. Together, Backers carry weight.

Declare an intention

On a company or a sector, with a ticket range. Paid, to show you are serious; transferable as long as it has not been converted.

Critical mass is reached

When the number of Backers and the total of their intentions cross a threshold, the licensed partner contacts the company and presents this demand.

The licensed partner structures

If the company’s expectations and the Backers’ converge, the partner builds a transaction and presents it directly to the Backers concerned.

Closing

Capital raise or sale of existing shares: small tickets are pooled in a common vehicle set up by the licensed partner. Each Backer decides whether to take part.

Uback does not advise, does not negotiate, collects nothing. Each transaction is run by the licensed partner of the company’s country, under the law that governs its shares.

Get notified when intentions open What happens after my declaration? Intention declarations open once the licensed partner signs · price per ticket band · valid 12 months · transferable credit

Challengers

A registered company raising funds that is not in the ranking will be able, for a fee, to appear in a separate list labelled “Challengers”, for a set period, with a memo available to verified Backers. The listing has no effect on the ranking. Not open yet.

Sponsored space · no Challenger listed yet

Radar · known eligible companies, not ranked

Sorted by date of last round, with no judgement and no AI call.

Frontier Health · United Kingdom · EuropeJun 2026 · USD 16M
Triomics · United States · North AmericaMay 2026 · USD 22M
Latent Health · United States · North AmericaMar 2026 · USD 80M
Avo · United States · North AmericaMar 2026 · USD 10M
voize · Germany · EuropeNov 2025 · USD 50M
Evidium · United States · North AmericaNov 2025 · USD 22M

Listed benchmarks

Not ranked: no intention is possible on a listed company.

Tempus AI · United StatesNASDAQ · TEM
Doximity · United StatesNYSE · DOCS
Health Catalyst · United StatesNASDAQ · HCAT
Yidu Tech · ChinaHKEX · 2158

Sources and method for this segment

Calendar. Global segment rankings are published twice a year. Next edition: January 1, 2027.

Eligibility. At least $1M raised including one equity round, non-listed company, main activity in this segment (AI scribes, clinical decision support, health-system data platforms and care coordination software). A company appears in one segment only.

Sources. STAT, Fierce Healthcare, Becker's Hospital Review, Axios Pro, Fortune, MobiHealthNews, Tech.eu, Business News Australia, Calcalist, Sacra, PR Newswire, BusinessWire, Wikipedia, company announcements.

Method and rules, common to all rankings →